Format

Send to

Choose Destination
Cardiovasc Diagn Ther. 2018 Oct;8(5):678-693. doi: 10.21037/cdt.2018.06.08.

Antiplatelet therapy in valvular and structural heart disease interventions.

Author information

1
Unit of Cardiac Sciences, Campus Bio-Medico University of Rome, Rome, Italy.

Abstract

Transcatheter interventions for valvular and structural heart diseases are rapidly expanding due to greater operators' experience and development of new generation devices associated with increased procedural safety. They represent the standard strategy for patients with prohibitive risk for open surgery. These procedures are associated with a significant occurrence of both thrombotic and bleeding complications, thus in this setting, even more than in other percutaneous procedures, the balance between thrombotic and bleeding risk is critical. This review describes the current data available on the antithrombotic management of patients undergoing transcatheter aortic valve implantation (TAVI), percutaneous mitral valve repair with the MitraClip system, percutaneous left atrial appendage occlusion and percutaneous patent foramen ovale (PFO)/atrial septal defects (ASD) closure.

KEYWORDS:

Valvular disease; antithrombotic therapy; transcatheter structural interventions

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Publication type

Publication type

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center